This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Summary: In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat NRAS- and NF1-driven tumors, with MGMT expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanistically, this triple cocktail suppresses expression of genes involved in DNA repair, leading to enhanced killing of melanoma cells.
See related article by Maertens et al., p. 526.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
April 2019
Volume 9, Issue 4
Volume 9, Issue 4
Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma
Jump to section
Advertisement